RootsAnalysis is pleased toannounce the publication of its recent study, titled, “Global Stem CellsMarket:Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic,Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal,Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow,Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, NeuralTissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent,Pluripotent))”.
The report features an extensive study of thecurrent market landscape, offering an informed opinion on the likely adoptionof these therapeutics over the next decade. The report features an in-depthanalysis, highlighting the capabilities of various stakeholders engaged in thisdomain. In addition to other elements, the study includes:
§ Adetailed assessment of the current market landscape of companies engaged in thedevelopment of stem cell therapies for treatment of wide range of clinicalconditions
§ Elaborateprofiles of key industry players engaged in the development of stem celltherapies (shortlisted on the basis of the product portfolio).
§ Aninsightful competitiveness analysis featuring a four-dimensional bubble chart,highlighting the key players in this domain.
§ Anassessment of over 20 commonly targeted therapeutic areas and details of stemcell-based therapies being developed to treat the same conditions.
§ Adetailed proprietary 2×2 representation that was developed to assess thecurrent market scenario (in terms of existing competition and growthopportunities) across emerging and established market segments.
§ Anin-depth analysis of more than 1,500 grants that have been awarded to researchinstitutes engaged in stem cell therapy-related projects, in the period between2015 and 2019 (till November)
§ Adetailed clinical trial analysis on more than 540 completed, ongoing andplanned studies of various stem cell therapies, highlighting prevalent trendsacross various relevant parameters.
§ Areview of the key aspects related to the manufacturing of stem cell therapies,including [A] a detailed discussion on processes and protocols, highlightingthe need to outsource various aspects of stem cell therapy development andmanufacturing operations, [B] an assessment of the current market landscape ofcontract manufacturers, providing information on stem cell-focused serviceproviders, and [C] an insightful Harvey ball analysis to identify the keyperformance indicators / key considerations that industry stakeholders arelikely to take into consideration while selecting a suitable CMO / CRO partner.
§ Adetailed market gap analysis in order to develop a realistic understanding ofthe demand and supply dynamics within this field, comparing both clinical andcommercial capabilities of therapy developers and the availability andcapabilities of contract manufacturers, across different geographies.
§ Anelaborate discussion on the various strategies that can be adopted by stem celltherapy developers across different stages of product development andcommercialization.
§ A detailed market forecast, featuring analysisof the current and projected future opportunity across key market segments(listed below)
§ Sourceof Stem Cell
§ Allogeneic
§ Autologous
§ Originof Stem Cell
§ Adult
§ Embryonic
§ Typeof Stem Cell
§ Hematopoietic
§ Mesenchymal
§ Progenitor
§ Others
§ Lineageof Stem Cell
§ Adipose Tissue
§ Bone Marrow
§ Cord Blood
§ Others
§ Route of Administration
§ Intraarticular
§ Intracoronary
§ Intramuscular
§ Intramyocardial
§ Intrathecal
§ Intravenous
§ Surgical Implantations
§ Others
§ Therapeutic Area
§ Autoimmune/ Inflammatory Disorder
§ CardiovascularDisorders
§ MetabolicDisorder
§ MusculoskeletalDisorders
§ OncologicalDisorders
§ NeurologicalDisorders
§ OphthalmicDisorders
§ Others
§ End Users
§ AmbulatorySurgery Centers
§ Hospitals
§ SpecialtyClinics
§ KeyGeographical Regions
§ NorthAmerica
§ Europe
§ Asia-Pacificand Rest of the World
§ Transcripts of interviews held with thefollowing senior level representatives of stakeholder companies
§ William L Rust (Founder and Chief Executive Officer, Seraxis)
§ Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)
§ Michel Revel (Co-Founder and Chief Scientist, Kadimastem)and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)
§ Kikuo Yasui (Director and Chief Operating Officer, Heartseed)
§ Gustav Steinhoff (Director and Chairman, Department ofCardiac Surgery, University of Rostock)
§ Gilles Devillers (President, Bio Elpida)
§ Fiona Bellot (Business Development Manager, Roslin CellTherapies)
§ David Mckenna (Professor and American Red Cross Chair inTransfusion Medicine, University of Minnesota)
§ Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
§ Mathilde Girard (Department Leader, Cell Therapy Innovationand Development, YposKesi)
Keycompanies covered in the report
§ Anterogen
§ Athersys
§ CHABiotech
§ Cytopeutics
§ HopeBiosciences
§ JapanRegenerative Medicine
§ LineageCell Therapeutics
§ OrchardTherapeutics
§ OsirisTherapeutics
§ PluristemTherapeutics
§ PromitheraBiosciences
§ Regenexx
§ StempeuticsResearch
§ SCMLife Sciences
§ TICEBA
Formore information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/
Other Recent Offerings
1. Stem Cell TherapyContract Manufacturing Market, 2019-2030
2. Antibody DrugConjugatesMarket (5th Edition), 2019-2030
3. Cell and AdvancedTherapies Supply Chain Management Market, 2019-2030: Focus on TechnologicalSolutions
4. Global T-Cell (CAR-T,TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
